First –in human, dose-escalating safety study of tissue factor specific antibody drug conjugate(Humax-TF-ADC) in patients with locally advanced and/or metastatic solid tumors known to express tissue factor

Cancer type: Multiple diagnosis, Solide tumores

Phase: I

Principal Investigator: Yachnin Jeffrey

Country: SE

Keywords: Sweden, Karolinska University Hospital

Status: Inclusion completed

Link to